• About
  • Jewish Community Directory
  • Subscription Information
  • Contact Us
American Jewish World
No Result
View All Result
  • News
    • All
    • Africa
    • Asia
    • Australia & New Zealand
    • Europe
    • Israel/Mideast
    • Latin America
    • Minnesota
    • US & Canada
    Shoah survivor, fundraiser Francelyne Lurie dies at 84

    Shoah survivor, fundraiser Francelyne Lurie dies at 84

    Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

    Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

    Israel, ‘an almost magical story’

    Israel, ‘an almost magical story’

  • Arts
    • All
    • Blue Box
    • Books & Literature
    • Music
    • Televison & Film
    • Theater & Performing Arts
    • Visual Arts
    Set a place for Andrew Zimmern at the dinner table

    Set a place for Andrew Zimmern at the dinner table

    Righteous Diplomats saved Jews in the Shoah

    Righteous Diplomats saved Jews in the Shoah

    Sharon’s got a brand-new bag

    Sharon’s got a brand-new bag

  • Lifestyle
    • All
    • Fashion
    • Food
    • Health & Wellness
    • Home & Garden
    • Travel & Culture
    Robyn Frank finds her niche in the cookie business

    Robyn Frank finds her niche in the cookie business

    Editorial: More from my European vacation

    Editorial: More from my European vacation

    Our Rosh Hashana special edition

    Our Rosh Hashana special edition

  • Editorial
  • Opinion
  • AJW Digital Archives
  • News
    • All
    • Africa
    • Asia
    • Australia & New Zealand
    • Europe
    • Israel/Mideast
    • Latin America
    • Minnesota
    • US & Canada
    Shoah survivor, fundraiser Francelyne Lurie dies at 84

    Shoah survivor, fundraiser Francelyne Lurie dies at 84

    Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

    Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

    Israel, ‘an almost magical story’

    Israel, ‘an almost magical story’

  • Arts
    • All
    • Blue Box
    • Books & Literature
    • Music
    • Televison & Film
    • Theater & Performing Arts
    • Visual Arts
    Set a place for Andrew Zimmern at the dinner table

    Set a place for Andrew Zimmern at the dinner table

    Righteous Diplomats saved Jews in the Shoah

    Righteous Diplomats saved Jews in the Shoah

    Sharon’s got a brand-new bag

    Sharon’s got a brand-new bag

  • Lifestyle
    • All
    • Fashion
    • Food
    • Health & Wellness
    • Home & Garden
    • Travel & Culture
    Robyn Frank finds her niche in the cookie business

    Robyn Frank finds her niche in the cookie business

    Editorial: More from my European vacation

    Editorial: More from my European vacation

    Our Rosh Hashana special edition

    Our Rosh Hashana special edition

  • Editorial
  • Opinion
  • AJW Digital Archives
No Result
View All Result
Morning News
No Result
View All Result
Home News Israel/Mideast

Israel gives new hope to patients with multiple myeloma

mordecai by mordecai
May 23, 2020
in Israel/Mideast, News
0
Share on FacebookShare on Twitter

By LARRY LUXNER

TEL AVIV — Shlomit Norman was only 42 when doctors diagnosed her with multiple myeloma — a bone marrow cancer with no known cure that rarely strikes people under the age of 65.

READ ALSO

Shoah survivor, fundraiser Francelyne Lurie dies at 84

Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

At the time, the youngest of her three boys was 10, and few patients with the disease survived for more than a couple of years.

“I told my best friend that she’d have to be in charge of my son’s bar mitzvah because I didn’t think I’d be around by then,” recalled Norman, who lives in Haifa.

Scientists attend the conference of AMEN, the Israeli Association of Myeloma Patients, at Tel Aviv University, May 2019. (Courtesy of AMEN)

But thanks to some innovative treatments with roots in Israeli research, Norman managed to outlive her initial prognosis and today leads a relatively stable life 12 years later.

“For the first 10 years after I was diagnosed, I was in a partial remission after my first bone marrow transplant and I had a fantastic quality of life,” she said. “But in 2016, I relapsed and had another transplant. Since then, I’m on maintenance medicine. Other than fatigue, and numbing in the hands and feet, I’m OK.”

According to the American Cancer Society, some 13,000 Americans die annually from multiple myeloma — commonly referred to as myeloma and first documented in 1844. But the typical life expectancy for patients following diagnosis has surged from two years to nearly 10. Some people now live for more than two decades with the illness.

A significant part of the global progress in treating multiple myeloma — in which the body produces too many plasma cells, “crowding out” other types of blood cells like platelets and red cells, all of which are necessary for optimal health — stems from research conducted in Israel.

In 2004, Aaron Ciechanover and Avram Hershko, scientists at Haifa’s Technion-Israel Institute of Technology, won the Nobel Prize in Chemistry, along with American biologist Irwin Rose, for their discovery years earlier of the ubiquitin proteasome system, a pathway responsible for the degradation of proteins within the cell.

This discovery was crucial to the creation of a whole class of treatments called proteasome inhibitors — drugs that slow the degradation of protein and thereby inhibit the cancer’s progress, explained Dr. Yael Cohen, head of myeloma services at Tel Aviv’s Ichilov Hospital, also known as the Sourasky Medical Center.

“Velcade, a drug which came out of that, was revolutionary, and it’s still used as first-line treatment for myeloma in most places around the world,” Cohen said.

Dr. Mark Israel, national executive director of the New York-based Israel Cancer Research Fund, which helped fund Ciechanover’s research and raises millions of dollars every year for cancer research in Israel, said the early work on proteasome inhibitors was groundbreaking even if the scientists at the time didn’t fully realize all its implications.

“When Ciechanover and Hershko got the Nobel Prize for something important, they had no idea they had discovered an efficacious drug target that inhibits multiple myeloma,” Israel said. “But if they had never done their work, everybody with the disease would still be dying quickly.”

Now there are second- and third-generation drugs based on the same research, such as carfilzomib, a selective proteasome inhibitor given to patients via an intravenous line, and ixazomib, the first oral therapy for multiple myeloma.

A more recent Israeli contribution to treating multiple myeloma was the invention of the CAR-T cell based on early work by Zelig Eshhar of the Weizmann Institute of Science in Rehovot.

T cells are a type of white blood cell that helps the human immune system fight harmful microbes. CAR-T cells are specially modified T cells designed to fight cancer.

“Eshhar’s idea was to take a T cell, modify it genetically by implanting a hybrid receptor that can target the cancer cell and have a second component that activates the T cell to kill the cancer cell,” Cohen said. “This was later developed for the treatment of leukemia and lymphoma, and we are now hoping to open CAR-T clinical trials in Israel to treat multiple myeloma in the next few months.”

Dr. Moshe Gat chairs the Israeli Multiple Myeloma Study Group, a gathering of 20 to 30 physicians who meet every few months to discuss current topics in myeloma. The group runs some joint clinical trials and advocates for better patient care and enhanced access to medication.

“When I was a fellow 15 years ago, the median survival for a patient with multiple myeloma was 2 1/2 years,” Gat said. “Since then it’s nearly quadrupled, and I don’t know what to say to a new patient since so many treatments are coming online.”

About 550 people in Israel are diagnosed with multiple myeloma each year, with some 3,500 patients living with the disease at any given time, according to Norman, who chairs AMEN-The Israeli Association of Myeloma Patients. The nonprofit, founded in 2005, advocates for multiple myeloma patients throughout Israel, including offering support through monthly meetings, empowerment workshops and an active Facebook group with more than 600 members.

“These days, people are living with myeloma much longer than they used to,” Norman said. “Even if they’re diagnosed at the age of 40, they will make it into their 60s.”

The most difficult thing about living with myeloma, Norman said, is the inevitability that her health will take a turn for the worse.

“For now there’s no cure, so even when you’re in remission you know it’s going to come back,” Norman said. “You don’t know when or how, but every physician you ask will say ‘You’re going to relapse.’ We always carry this fear.”

While the median age for a multiple myeloma diagnosis is 70, some patients get it much younger. Norman says it is outdated thinking to view it as a disease of the elderly.

Myeloma is one of the many cancers that the Israel Cancer Research Fund is targeting through research.

“We’re trying to use the best minds in the world to ask the fundamental questions about cancer cells: How do they grow, how do they metastasize, how do they invade normal tissue and ultimately do things which make people sick and die?” said Israel of the ICRF. “We contribute to the fund of knowledge on which cancer interventions are based. This is where the investment really counts.”

***

This article was sponsored by and produced in partnership with the Israel Cancer Research Fund, whose ongoing support of these and other Israeli scientists’ work goes a long way toward ensuring that their efforts will have important and lasting impact in the global fight against cancer. This article was produced by JTA’s native content team.

Related Posts

Shoah survivor, fundraiser Francelyne Lurie dies at 84
Minnesota

Shoah survivor, fundraiser Francelyne Lurie dies at 84

May 21, 2023
Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67
Minnesota

Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

May 21, 2023
Israel, ‘an almost magical story’
Books & Literature

Israel, ‘an almost magical story’

May 19, 2023
Vic Rosenthal was a tireless organizer for social justice
Minnesota

Vic Rosenthal was a tireless organizer for social justice

April 20, 2023
Holocaust, genocide education bill progresses in Legislature
Minnesota

Holocaust, genocide education bill progresses in Legislature

April 20, 2023
A novel about the controversial Transfer Agreement
Books & Literature

A novel about the controversial Transfer Agreement

April 20, 2023
Next Post

Rabbi helps dedicate a memorial to Ukrainian group that collaborated with the Nazis

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECENT ARTICLES

Shoah survivor, fundraiser Francelyne Lurie dies at 84

Shoah survivor, fundraiser Francelyne Lurie dies at 84

May 21, 2023
Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

Temple Israel’s Rabbi Simeon ‘Sim’ Glaser dies at 67

May 21, 2023
Editorial: A mosque is like a synagogue

Editorial: A mosque is like a synagogue

May 21, 2023
Israel, ‘an almost magical story’

Israel, ‘an almost magical story’

May 19, 2023
Set a place for Andrew Zimmern at the dinner table

Set a place for Andrew Zimmern at the dinner table

May 19, 2023

About

Since 1912 the AJW has served as an important news resource for the Jewish community. The Jewish World unites the main Jewish communities in St. Paul and Minneapolis, as well as those in Duluth, Rochester and smaller cities, and bridges the divides between the various Jewish religious streams.

Quick Links

  • About the AJW
  • Advertising Information
  • Submission Guidelines
  • Subscription Information
  • Jewish Community Directory

Contact Us

The American Jewish World
3249 Hennepin Ave., Suite 245
Minneapolis, MN 55408

Tel: 612.824.0030 / Fax: 612.823.0753
editor@ajwnews.com

  • Buy JNews
  • Landing Page
  • Documentation
  • Support Forum

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Homepages
    • Home Page 1
  • News
  • Food
  • Health & Wellness
  • Lifestyle
  • Opinion

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.